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Abstract
Background: Gliomas are the most common neoplasm of the brain. High-grade gliomas often resist treatment
even with aggressive surgical resection and adjuvant radiation and chemotherapy. Despite the combined
treatment, they frequently recur with the same or higher-grade histology. Genetic instability is commonly
associated with inactivation of the normal DNA repair function and tumour suppressor genes as well as activation
of oncogenes resulting from alterations of promoter hypermethylation, but the molecular mechanisms of the
histological and clinical progression of gliomas are still poorly understood.
Methods: This study involved longitudinal analysis samples of primary and recurrent gliomas to determine
whether the progression of low- and high-grade gliomas is associated with the promoter methylation of the
DNMT1, MGMT and EGFR genes by PCR-based restriction enzyme assay. Epigenetic inactivation of these three
important glioma-associated genes was analyzed in paired biopsy samples from 18 patients with tumour
recurrence.
Results: The methylation analysis of the CpG sites in the DNA methyltransferase (DNMT1) promoter revealed a
total of 6 hypermethylations (6/18), the methylguanine-DNA methyltransferase (MGMT) promoter revealed a total
of 10 hypermethylations (10/18) and the epithelial grow factor receptor (EGFR) promoter revealed a total of 12 (12/
18) hypermethylations respectively in recurrent gliomas. The results demonstrated that DNMT1 promoter
hypermethylation does not occur in low-grade gliomas, it was mainly observed in secondary glioblastomas.
Additionally, the MGMT and EGFR promoter was hypermethylated in both low-and high-grade GLs and their
corresponding histological transformed GLs.
Conclusion: This study has provided further evidence that the histological transformation and progression of
gliomas may be associated with the inactivation of the EGFR and MGMT genes. It seems that EGFR and MGMT
promoter hypermethylations are early events in the clonal evolution of gliomas and this gene inactivation has
proved to be stable even in tumour recurrence. However, the DNMT hypermethylation is a late part of glioma
progression.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1935054011612460
Background
High-grade gliomas (GLs) often resist such treatment as
complete surgical resection and chemotherapy in combi-
nation with radiation therapy. The lesions frequently
recur after an asymptomatic period [1]. Most malignant
gliomas are glioblastomas (GB) with clinical, histological,
genetic and prognostic heterogeneities. Depending on
their clinical and genetic characteristics, GBs have been
divided into primary and secondary subtypes [2]. Pri-
mary GBs may develop rapidly without clinical or histo-
logical evidence of a precursor lesion with a low grade
of malignancy. Secondary GB is the final stage of pro-
gression of a low-grade or anaplastic astrocytoma. Sev-
eral lines of evidence indicate that multiple genetic
abnormalities are associated with the development of
GBs, such as the inactivation or amplification of several
genes [3,4], the loss of heterozygosity of different chro-
mosomes and microsatellite instability [5,6] with
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epidermal growth factor receptor (EGFR) proto-onco-
gene is a member of the HER/ERB-B family of trans-
membrane tyrosine receptor kinases. The overexpression
of EGFR is responsible for cell proliferation, tumour cell
migration and progression, as well as for the prognosis
and the survival [8]. The complex genetic characteriza-
tion indicates that primary GB is predominantly asso-
ciated with the overexpression and amplification of
EGFR with unfavourable biological behaviour. However,
the EGFR amplification is less specific in secondary GB,
though it has been shown that EGFR overexpression is a
relatively late event in the dedifferentiation of glia-tumor
cells. The epigenetic regulation and transcriptional inacti-
vation of EGFR by promoter hypermethylation may play
role in an absence of EGFR gene expression during GL
progression. Furthermore, the hypermethylation of EGFR
m i g h tb eap o s s i b l ee x p l a n a t i o no ft h es i l e n c eo ft h i s
gene in secondary GB. Although a large numbers of epi-
g e n e t i cd a t ah a v ea c c u m u l a t e db u tn of o l l o w - u ps t u d i e s
have been reported in which the promoter methylation
of EGFR genes in tumour cells of primary and secondary
GB were compared before and after the clinical recur-
rence and histological progression. The characterization
of the EGFR methylation status of GB seems to be a criti-
cal issue in the delineation of the prognosis of these
tumours.
Recent epigenetic studies have evidence that the pro-
moter hypermethylation of CpG islands can be regarded
as a common mechanism of inactivation of tumour-
related genes [9]. The methylation of genomic DNA is
performed by DNA methyltransferase (DNMT) which
transfers the methyl groups to cytosine residues during
DNA replication [10]. Aberrant DNA methylation has
been reported in human cancer [11-13] with the invol-
vement of the hypermethylation of tumour suppressor
genes and the hypomethylation of oncogenes [14]. No
studies on the DNMT methylation status of recurrent
GLs are available.
Methylguanine-DNA methyltransferase (MGMT) is a
DNA repair protein that directly and specifically
removes mutagen DNA precursor and consequently
causes resistance to alkylating drugs. The intracellular
level of MGMT varies among tumours of the same his-
tological type. Approximately one-third of GLs lack
MGMT [15]. The MGMT gene does not commonly
undergo mutation or deletion. A reduced MGMT
expression may be caused by epigenetic inactivation.
Promoter hypermethylation of MGMT is frequent in the
process leading to the development of secondary GBs
[16] and oligodendrogliomas [17].
To determine whether the progression of high-grade
GLs is associated with the promoter methylation of the
EGFR, DNMT1 and MGMT genes, we performed
methylation analysis in paired samples of primary and
recurrent GLs with or without histological progression.
The results indicated that the hypermethylation of the
EGFR and MGMT genes occurs in both primary and
recurrent high-grade GLs and that the methylation pro-
file was stable during GL progression. The promoter
hypermethylation of the EGFR and MGMT genes sug-
gests an important epigenetic regulation of GL progres-
sion. DNMT1 hypermethylation was not found in low-
grade GLs, it was associated with secondary GBs.
Materials and methods
Pathological samples
Sequential brain tumour biopsy samples from 18 patients
with GL were selected for the molecular analyses. All
tumour specimens were cut into two; one half of the
sample was paraffin-embedded for histological diagnosis
of the tumours, while the other half were frozen for
molecular analysis. The histological findings on the two
halves were identical. Neither the high-grade nor the
low-grade GLs displayed morphological heterogeneity.
During the selection of the slides, the necrotic areas were
omitted. Tissues derived from paraffin-embedded mate-
rial and frozen samples were sufficient for the histological
diagnosis and DNA preparation (all DNA preparations
with a high standard DNA concentration).
Diagnoses were established by means of the WHO
classification [18]. The histological findings on the first
biopsy were classified into three GL categories: diffuse
astrocytomas (A2) (cases 1-6); anaplastic astrocytoma
(A3) (cases 7-10) and glioblastoma (GB) (cases 11-18)
(Figure 1). In 8 patients, the histological picture of the
second biopsy sample was identical with that of the pri-
mary tumour. In 10 patients, the histological finding on
the primary tumour was transformed into the higher-
grade at the second biopsy. Sixteen patients received
postoperative radiation therapy, 10 patients underwent
postoperative chemotherapy such as a Temodal and
Carbo/VP-16 combination and only 1 patient did not
participate in postoperative therapy (Table 1).
DNA extraction
In each case, genomic DNA was extracted from formal-
dehyde-fixed and paraffin-embedded tissue samples and
cryopreserved tumour samples, using DNA extraction
kits (paraffin-embedded tissue with the High Pure PCR
Template Preparation Kit from Roche Diagnostics, USA,
and frozen tissue with the NucleoSpin Tissue Kit from
Manchery-Nagel, Germany) according to the manufac-
turer’s instructions.
Analysis of EGFR, DNMT1 and MGMT methylation
Methylation-specific PCR [19] was used to analyze geno-
mic DNA samples for the presence of hypermethylation
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g e n e s .T h eg e n es e q u e n c ec o n t a i n sH p a I Ia n dM s p I
restriction sites. DNAs were digested with HpaII (Pro-
mega Corporation, Madison, WI, USA) and MspI (Pro-
mega Corporation, Madison, WI, USA) restriction
endonucleases in a volume of 20 μl, according to the
manufacturer’s instructions. Digested and undigested
DNAs were PCR-amplified by using primer pairs for
EGFR exon 18: 5’- AGGCGTACATTTGTCCTTCC-3’
(forward) and 5’-TGGAGTTTCCCAAACACTCAG-3’
(reverse), DNMT1 exon 23: 5’-GCAGATGCACTGTG-
GAGAAG-3’ (forward) and 5’- CTCTTCTCAGGGG-
CAAACAG-3’(reverse), MGMT exon 5: 5’- ACAGGT
GTTTGCCCGTTTAG-3’ (forward) and 5-AAGTGT
TGGAGTGGGTGGAG-3’(reverse).
PCR was performed with a Perkin-Elmer Model 2700
PCR system (Foster City, CA, USA) with the following
PCR program: initial denaturation at 94 oC for 5 min,
followed by 30 cycles of denaturation at 94 oC for 45 s,
annealing at 60 oC for 45 s, extension at 72 oC for 45 s,
and a final elongation step at 72 oC for 5 min. Electro-
phoretic separation was achieved in 2% agarose gels,
with staining with ethidium bromide, and visualization
under UV illumination. Unmethylated and methylated
controls were included in all reactions.
Immunohistochemical reaction of EGFR, DNMT1 and
MGMT
After microwave antigen retrieval procedure the sections
were incubated with the anti-EGFR monoclonal anti-
body (DAKO Glostrup, Denmark, RTU), anti- DNMT1
monoclonal antibody (BIOZOL, Germany 1:500) and
anti-MGMT monoclonal antibody (Novobius, USA
1:50). Binding was visualized with biotinylated IgG using
the avidin-biotin peroxidase detection system (Vectas-
tain ABC Universal Elite Kit, Vector) and 3,30-diamino-
benzidine (DAB) as the chromogenic substrates. Control
sections were treated similarly except the primary anti-
body was omitted from the procedure. The quality of
immunostaining slightly varied due to the degree of fixa-
tion which differed in each case.
Results
Analysis of DNMT1 promoter methylation in primary and
recurrent GLs
To evaluate the methylation of CpG sites in the
DNMT1, EGFR and MGMT promoters, PCR products
amplified from undigested, and from HpaII and MshI-
digested DNAs were evaluated in parallel. In each case,
the results of DNMT1, EGFR and MGMT promoter
methylation of the first and second biopsy samples were
compared (Table 2).
DNMT1 promoter methylation was present in 6 of the
18 cases (33.3%) in 5 primary and 6 recurrent GLs. In 5
samples of GLs and the corresponding recurrent sam-
ples (cases 7, 8, 10, 11 and 12) and in one only recur-
rent sample (case 9), the DNMT1 promoter region was
resistant to digestion by HpaII and sensitive to digestion
by MspI. The representative cases are illustrated in Fig-
ure 2. At the first biopsy all of the HpaII-resistant cases
were high-grade GLs, involving either anaplastic astrocy-
toma or GB. At the second biopsy, all of the HpaII-
Figure 1 Photomicrographs show the different histological type of recurrent GL’s. Moderately cellular tumour composed of uniform
astrocytic cells concerning diffuse astrocytoma, Grade II (A). Histological features of anaplastic astrocytoma with hypercellularity and
hyperchromatic, irregular nuclei, Grade III (B). Glioblastoma with high grade anaplasia and giant cells, Grade IV (C).
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mary biopsies were anaplastic astrocytomas that trans-
formed to GBs as in case 9. In cases 11 and 12, both
biopsies were GBs that showed no histological altera-
tion. All those low-grade GLs including a diffuse astro-
cytoma (case 1-6), at the first biopsy, that showed
histological progression transform to anaplastic GLs.
The DNMT1 promoter region was sensitive to digestion
by both HpaII and MspI in only 1 anaplastic
astrocytoma (case 9) and 6 primary GBs that exhibited
no histological alteration (cases 13-18),
Analysis of EGFR promoter methylation in primary and
recurrent GLs
EGFR promoter methylation was present in 12 of the 18
cases (66.6%) in 11 primary and 12 recurrent GLs. In 11
samples of GLs and the corresponding recurrent sam-
ples (cases 2, 4, and 7-15) and in one second sample
Table 1 Summary of the clinical and histological data of 18 patients with primary and recurrent gliomas
Case Age (y) Sex Site of tumor Interval of biopsies (m) Survival (m) Histology P/R Adjuvant therapy
1 20 M RTL 15 ALIVE PA2 R
RTL RA3 -
2 48 M LTL 24 ALIVE PA2 R
LTL RA3 -
3 55 M RFL 13 14 PA3 -
RFL RA3 -
4 50 F LTL 74 ALIVE PA2 R
LTL RA3 T
5 30 M RFL 662 ALIVE PA2 R
RFL RA3 -
6 41 F RTL 42 64 PA2 R
RTL RA3 -
7 50 M LOL 9 18 PA3 R
LOL RGB T
8 15 F LFL 31 49 PA3 R
LFL RGB CVP
9 27 F RFL 33 98 PA3 R
RFL RGB T
10 56 F RPL 12 32 PA3 R
RPL RGB -
11 69 F RFL 11 16 PGB R
RFL RGB -
12 44 M LPL 3 6 PGB R
LPL RGB -
13 47 M LFL 9 12 PGB -
LFL RGB T
14 55 M LTL 13 19 PGB R
LTL RGB T
15 62 M RFL 6 18 PGB R
RFL RGB T
16 54 M RTL 12 14 PGB R
RTL RGB T
17 41 M RTL 10 24 PGCGB R
RTL RGCGB T
18 17 F RTL 15 29 PGCGB R
RTL RGCGB CVP
Abbreviations: Histology: P for primary and R for recurrence; A2, diffuse astrocytoma; A3, anaplastic astrocytoma; GB, glioblastoma; GCGB, giant cell glioblastoma;
LFL, left frontal lobe; RFL, right frontal lobe; LTL, left temporal lobe; RTL, right temporal lobe; RPL, right parietal lobe; ROL, right occipital lobe; R, radiotherapy;
CVP, Carbo/VP-16 chemotherapy; T, Temodal; female; M, male; y, year; m, month; Interval is the time in months between the two biopsies
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digestion by HpaII and sensitive to digestion by MspI
(Figure 2). As concerns the first biopsy samples, the
HpaII-resistant cases were either low- or high-grade
GLs; at the second biopsy, including anaplastic GL or
GB all of the HpaII-resistant cases were high-grade
tumour. Low-grade GLs, the diffuse astrocytomas (cases
2 and 4), and their corresponding high-grade tumours
were HpaII-resistant. Four primary biopsy cases categor-
ized as anaplastic astrocytoma (7-10) that transformed
into GBs and both samples of 5 primary GBs (cases 11-
15) were also HpaII-resistant. Only one anaplastic astro-
cytoma was HpaII-resistant (case 5). The other low-
grade GLs, diffuse astrocytoma (cases 1, 3, 5 and 6) that
showed histological progression to anaplastic GLs, 1 pri-
mary GB (case 16) and 2 giant cell GB (cases 17 and 18)
the EGFR promoter region was sensitive to digestion by
both HpaII and MspI.
Analysis of MGMT promoter methylation in primary and
recurrent GLs
MGMT promoter methylation was present in 10 of the
18 cases (55.5%), in 9 primary and 10 recurrent GLs. In
9 samples of GLs and the corresponding recurrent sam-
ples (cases 3-5, 7, 8, 10, 12, 14 and 16) and in 1 recur-
rent sample (case 13), the MGMT promoter region was
resistant to digestion by HpaII and sensitive to digestion
by MspI (Figure 2). At the first biopsy, the HpaII-resis-
tant cases proved to be both low- and high-grade GLs.
All of the HpaII-resistant cases at the second biopsy
were high-grade tumours including anaplastic GL or
GB. Low-grade diffuse astrocytomas (cases 3, 4, 5) were
Table 2 Summary of methyaltion conditions and immunoreactivity of 18 patients with primary and recurrent gliomas
Cases HT DNMT EGFR MGMT
PGL RGL PGL RGL PGL RGL
1A 2 ® A3
2A 2 ® A3 --
3A 3 ® A3 --
4A 2 ® A3 ----
5A 2 ® A3 +--
6A 2 ® A3
7A 3 ® G B ------
8A 3 ® G B ------
9A 3 ® GB ---
10 A3 ® G B ------
11 GB ® G B ----
12 GB ® G B ------
13 GB ® GB -- -
14 GB ® GB ----
15 GB ® GB --
16 GB ® GB --
17 GCGB ® GCGB
18 GCGB ® GCGB
Abbreviations: no mark, hypermethylation; oval mark, unmethylation; PGL, primary glioma; RGL, recurrent glioma;HT, histological tranformation; A2, diffuse
astrocytoma; A3, anaplastic astrocytoma; GB, glioblastoma; GCGB, giant cell glioblastoma; + positive immunoreactivity; - negative immunoreactivity
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8 and 10) that transformed into GBs were resistant to
digestion by HpaII. In 3 primary GBs (cases 12, 14 and
16), both biopsies were HpaII-resistant; in case 13, only
second biopsy was HpaII-resistant. The MGMT promo-
ter region of the progressive low-grade astrocytoma
(cases 1, 2 and 6), 1 secondary GB (case 9) and 5 pri-
mary GBs (cases 11, 13, 15, 17 and 18) were sensitive to
digestion by both HpaII and MspI.
DNMT1, EGFR and MGMT immunolabeling in recurrent
GLs
Immunohistochemical reaction confirmed results of
methylation analysis. DNMT1-immunoreactivity was
present at all unmethylated samples (case 1-6 and case
1 3 - 1 8a n df i r s tb i o p s yo fc a s e9 ) .H o w e v e r ,a l lm e t h y -
lated tumours showed negative immunohistochemistry
(case 7-12 except first biopsy of case 9).
EGFR immunohistochemical reactions revealed no
labelling in methylated samples (cases 2, 4, and 7-15)
and both biopsies of case 16. The other tumour’sp a i r s
showed membrane immunpositivity (cases 1, 3, 5, 6, 17
and 18).
MGMT nuclear immunoreactivity was present at all
unmethylated samples (cases 1, 2, 6, 9, 11, 15, 17 and
18). However, all methylated tumours showed negative
immunohistochemistry (case 3-5, 7, 8, 10, 12-14 and
16). The representative results are illustrated in Figure 3.
Discussion
Genetic instability can be generated by the epigenetic
regulation of multiple genes, including oncogenes,
tumour suppressor genes and mismatch repair genes
[20]. The methylation mechanism plays an important
role in the pathogenesis of the recurrence of GLs [21]. In
order to establish whether the histological transformation
and clinical progression of GLs are associated with the
epigenetic inactivation of three important GL-associated
genes, paired biopsy samples were analyzed for the func-
tionally important methylated exons of the DNMT1,
MGMT and EGFR genes to elucidate their methylation
patterns. No DNMT promoter methylations were found
in the low-grade GLs. Promoter methylations of DNMT1
were not characteristic (2/8) in primary GBs; all second-
ary GBs were hypermethylated (4/4). This is the first pre-
sentation that the low-grade GLs are not and primary
GBs are less associated with DNMT1 gene hypermethyla-
tion. These findings suggest that the methylation
mediated normal transcriptional regulation of DNMT1
gene has being worked in the early stage of GLs’ prolif-
eration. Additionally, the DNMT1 gene inactivation by
promoter methylation develops in a later stage of GLs, in
secondary GB. We have assumed that the DNMT1 gene
is involved in normal DNA methylation in low grade
gliomas. However, the epigenetic inactivation of DNMT1
gene plays a part in the pathogenesis of anaplastic astro-
cytoma progression.
Figure 2 Representative methylation analysis of CpG islands in the MGMT, EGFR and DNMT1 promoter in GL samples of cases 6, 12
and 16. C, undigested DNA samples; P, b2- microglobulin as a positive control; N, no DNA sample as a negative control; U, unmethylated DNA
samples; M, methylated DNA samples, m, molecular weight marker
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low- and high-grade GLs. Furthermore, the hypermethy-
lation accumulated during histological progression of
the GLs. Our results demonstrate that the development
of both primary and recurrent GLs is associated with
MGMT gene hypermethylation and it is more frequent
in high-grade GLs [16]. The distribution of MGMT pro-
moter hypermethylation shows that it starts to develop
at an early stage of GL and the gene inactivation is
stable even on tumour progression. The promoter
methylation of the MGMT gene compromises DNA
repair and has been associated with a longer progres-
sion-free survival in GLs’ patients [22]. Further, recent
studies indicate that MGMT promoter methylation has
strong prognostic relevance even in anaplastic gliomas
but irrespective of sensitivity of alkiling agents [23].
Several lines of evidence suggest that the hypermethy-
lation of oncogenes and tumour suppressor gene partici-
pate in the development of GLs pointing to a wide-
ranging increase in methylation activity in glial tumour
g e n e s i s[ 2 4 , 2 5 ] .T h i si ss u p p o r t e db yt h ef i n d i n g st h a t
EGFR promoter hypermethylation occurs in solid
tumour cell lines, e.g. breast, colon and lung cancers
[26]. The EGFR promoter was hypermethylated in both
low- and high-grade GLs and their corresponding histo-
logical transformed GLs, but the number of alterations
was not increased considerably in progression. Our
results also indicate that the development of both type
of GBs are associated with EGFR gene hypermethyla-
tion. These data suggest that de novo GBs are regulated
by epigenetic inactivation of EGFR gene besides the
well-known EGFR gene amplification and overexpres-
sion (2). On the other hand, the hypermethylation of
the EGFR promoter is typical event of secondary GBs.
Additionally, tumours with EGFR hypermethylation are
more resistant to tyrosine kinase inhibitor, which indi-
cates a poorer prognosis [26,27]. The current evidence
indicates that gene transcriptional regulation begins in
the early stage of tumour genesis and the change in
DNA methylation is a principal component of tumour
Figure 3 Photomicrographs show immunohistochemical reactions of EGFR, MGMT and DNMT antibodies. Recurrent anaplastic
astrocytoma (case 6) was strong EGFR membrane positive but no reaction in glioblastoma (case 10) (A). MGMT immunostaining of nuclei with a
weak cytoplasmic staining in primary glioblatoma (case 11) but no reaction in anaplastic astrocytoma (case 7) (B). Recurrent anaplastic
astrocytoma (case 4) was DNMT cytoplasmic positive but no reaction in seconder glioblastoma (case 8) (C).
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effectivity of chemotherapy [23].
The simultaneous evaluation of methylation analysis
and immunohistochemical reaction revealed similar
results, suggesting that CpG methylation mechanism
regulates gene activation during glioma progression. It
seems that the methylation mediated inactivity of genes
associated with loss of protein expression in recurrent
GL’s. However, the inverse relation between methylation
status and immunoreactivity in case 5, 13 and 16 is
probably caused by genetic abnormalities including
overexpression or deletion of EGFR and MGMT genes.
In conclusion, this study has provided epigenetic evi-
dence that promoter hypermethylation of all three
important GL-associated genes, DNMT1, MGMT and
EGFR may play a role in GL progression and the inacti-
vation of these genes is stable even as concerns tumour
recurrence. EGFR and MGMT promoter hypermethyla-
tion was revealed in low-grade GLs and their anaplastic
counterparts. This study has provided an indication that
the histological transformation and recurrence of GLs
may be associated with EGFR and MGMT promoter
hypermethylation, which are early events in the develop-
ment or clonal evolution of GLs. Additionally, DNMT1
gene is still working entirely in the early GLs’ prolifera-
tion, the hypermethylated inactivation associated mainly
with late phase of GLs’ progression.
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